bladder cancer phenotype
Evidence from:
primary |
all sources
Related entities (4)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| NAT2 | protective_against | bladder cancer | — | 1 |
| NAT2 | risk_factor_for | bladder cancer | — | 1 |
| risk allele | risk_factor_for | bladder cancer | — | 1 |
| smoking | risk_factor_for | bladder cancer | — | 1 |
Mentioned in (59)
Papers in which this entity is mentioned.
- A guide to transcriptomic deconvolution in cancer. (2026)
- Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types. (2026)
- Three-dimensional genome landscape of primary human cancers. (2025)
- Transcription start sites experience a high influx of heritable variants fueled by early development. (2025)
- Transient loss of Polycomb components induces an epigenetic cancer fate. (2024)
- Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. (2024)
- A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges. (2024)
- Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients (2023)
- Predicting tumour content of liquid biopsies from cell-free DNA. (2023)
- Towards understandings of serine/arginine-rich splicing factors. (2023)
- RNA splicing dysregulation and the hallmarks of cancer. (2023)
- DNA methylation in relation to gestational age and brain dysmaturation in preterm infants. (2022)
- Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. (2021)
- Alternative splicing: Human disease and quantitative analysis from high-throughput sequencing. (2021)
- Evaluating the transcriptional fidelity of cancer models. (2021)
- Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. (2021)
- Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases. (2021)
- DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. (2020)
- Pan-cancer analysis of whole genomes. (2020)
- Cancer PRSweb: An Online Repository with Polygenic Risk Scores for Major Cancer Traits and Their Evaluation in Two Independent Biobanks. (2020)
- Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. (2020)
- The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. (2019)
- A Compendium of Mutational Signatures of Environmental Agents. (2019)
- Comprehensive analysis of structural variants in breast cancer genomes using single molecule sequencing (2019)
- CNVScope: Visually Exploring Copy Number Aberrations in Cancer Genomes. (2019)
- Pan-cancer whole-genome analyses of metastatic solid tumours. (2019)
- Enter the Matrix: Factorization Uncovers Knowledge from Omics. (2018)
- Enhanced detection of circulating tumor DNA by fragment size analysis. (2018)
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes (2018)
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. (2017)
- Universal Patterns of Selection in Cancer and Somatic Tissues. (2017)
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. (2017)
- A method to reduce ancestry related germline false positives in tumor only somatic variant calling. (2017)
- Comprehensive Analysis of Hypermutation in Human Cancer. (2017)
- Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. (2016)
- Substantial contribution of extrinsic risk factors to cancer development. (2016)
- Oxidative stress signaling to chromatin in health and disease. (2016)
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. (2016)
- APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. (2016)
- Development and clinical application of an integrative genomic approach to personalized cancer therapy. (2016)
- Systematic pan-cancer analysis of tumour purity. (2015)
- The landscape of long noncoding RNAs in the human transcriptome. (2015)
- Genome-wide analysis of noncoding regulatory mutations in cancer. (2014)
- Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. (2014)
- Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. (2014)
- Mutational heterogeneity in cancer and the search for new cancer-associated genes. (2013)
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. (2013)
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. (2013)
- Pan-cancer patterns of somatic copy number alteration. (2013)
- Gene-environment interactions in cancer epidemiology: a National Cancer Institute Think Tank report. (2013)
- Effects of prenatal exposure to sodium arsenite on motor and food-motivated behaviors from birth to adulthood in C57BL6/J mice. (2012)
- Regulation of chromatin by histone modifications. (2011)
- Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood. (2011)
- Distribution of allele frequencies and effect sizes and their interrelationships for common genetic susceptibility variants. (2011)
- The genetic interpretation of area under the ROC curve in genomic profiling. (2010)
- Gene--environment-wide association studies: emerging approaches. (2010)
- Tackling the widespread and critical impact of batch effects in high-throughput data. (2010)
- Adrenomedullin signaling is necessary for murine lymphatic vascular development. (2008)
- MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. (2008)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| bladder cancer | phenotype | 55 | 120 |
| bladder carcinoma | phenotype | 5 | 7 |